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Introduction: Lung adenocarcinoma patients harboring EGFR acti-
vating mutations attain improved progression-free survival (PFS) 
with treatment with epidermal growth factor receptor tyrosine kinase 
inhibitors. However, patients ultimately relapse, indicating that other 
genetic factors could influence outcome in such patients. We hypoth-
esized that PFS could be influenced by the expression of genes in 
DNA repair pathways.
Methods: We examined the mRNA expression of C terminus-bind-
ing protein–interacting protein and Lin11, Isl-1, and Mec-3 domain 
only 4 (LMO4) in pretreatment tumor samples from 91 erlotinib-
treated advanced non–small-cell lung cancer patients with EGFR 
mutations in whom breast cancer gene 1 (BRCA1) expression and the 
concomitant presence of the EGFR T790M mutation had previously 
been assessed. Gene expression was analyzed by polymerase chain 
reaction, using β-actin as endogenous gene. Results were correlated 
with PFS and overall survival.
Results: In patients with low LMO4 levels, PFS was 13 months, 
whereas it was not reached for those with high LMO4 levels (p = 
0.03). In patients with low levels of both BRCA1 and LMO4, PFS was 
19 months whereas it was not reached in those with low BRCA1 and 
high LMO4 mRNA levels (p = 0.04). In patients with high BRCA1 
and low LMO4 levels, PFS was 8 months, whereas it was 18 months 
in those with high levels of both genes (p = 0.03).
Conclusions: Low BRCA1 and high LMO4 levels were associated 
with longer PFS to erlotinib. Baseline assessment of BRCA1 and 
LMO4 mRNA expression can help predict outcome to erlotinib.
Key Words: Breast cancer gene 1, Lin11, Isl-1, and Mec-3 domain 
only 4, EGFR, Non–small-cell lung cancer, Erlotinib.
(J Thorac Oncol. 2013;8: 295-300)
With a greater understanding of tumor biology, novel molecular-targeted strategies have been evaluated as a 
therapeutic approach for treating non–small-cell lung cancer 
(NSCLC).1 Recent studies have established the efficacy of 
the epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKIs) erlotinib and gefitinib in patients with EGFR 
activating mutations (deletion in exon 19 or L858R in exon 
21), who have attained progression-free survival (PFS) of 9 
to 11 months.2–7
However, despite promising initial responses, all patients 
ultimately progress because the efficacy of EGFR TKIs is lim-
ited by either primary or acquired resistance after therapy. The 
detection of biomarkers of acquired resistance is thus critical 
for maximizing the benefits of TKI therapy.8 The concomitant 
EGFR T790M mutation in exon 20, mesenchymal epithelial 
transition factor amplification, hepatocyte growth factor over-
expression, activation of insulin-like growth factor 1 receptor, 
and other factors have been associated with acquired resis-
tance to EGFR TKIs.9–11
DNA repair as a therapeutic target has recently received 
considerable attention owing to the promise of drugs that target 
tumor-specific DNA-repair enzymes and improve the efficacy 
of chemotherapy.12 The breast cancer gene 1 (BRCA1) plays 
a central role in DNA repair and is also involved in mitosis 
and cell division.13 High BRCA1 levels are associated with 
platinum resistance in vitro.14 In NSCLC patients receiving 
induction chemotherapy with cisplatin plus gemcitabine, low 
BRCA1 mRNA levels were associated with longer overall 
survival (hazard ratio [HR], 0.206; p = 0.026),15 and with a 
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radiographic response rate (partial response or stable disease) 
of 100%, whereas in chemonaive patients with resected 
NSCLC, high BRCA1 levels correlated with shorter overall 
survival (HR, 1.98; p = 0.02) and a radiographic response rate 
of 91.6%.16 The BRCA1-C-terminus (BRCT) domain and its 
capability to bind phosphorylated protein is required for the 
tumor-suppressor function of BRCA1.17
Our previous findings support a predominant predic-
tive role of BRCA1 in patients with EGFR mutations through 
an H2AX-independent pathway.18 The DNA breakage caused 
by erlotinib is different from that caused by radiotherapy 
or platinum-based chemotherapy, and BRCA1 by itself can 
be a relevant predictive biomarker.18 Erlotinib can suppress 
homology-directed repair and increase basal levels of γ-H2AX 
foci, which are indicative of an accumulation of DNA dou-
ble-strand breaks, where BRCA1 plays an important role. In 
experimental models, erlotinib sensitivity was highly influ-
enced by BRCA1 status.18
LIM (named for the initials of the three homeodomain 
proteins Lin11, Isl-1 and Mec-3) domain only 4 (LMO4) and 
C terminus-binding protein–interacting protein (CtIP) both 
interact with the BRCT domain of BRCA1.19 The precise con-
tact residues are likely to differ because tumor-derived muta-
tions in the BRCT domain abolish the interaction of BRCA1 
with CtIP but not with LMO4.19,20
LMO4 is a member of the LIM-only (LMO) family 
of transcriptional regulators, consisting of LMO1–4 and is 
expressed primarily in epithelial-derived tissues.21 LMO1–4 
act as molecular adaptors, providing a scaffold for multipro-
tein complexes of DNA-binding factors and transcriptional 
regulatory proteins, which play essential roles in cell fate 
determination, tissue patterning, and organ development.22 
The expression profile of LMO4 suggests that it is an impor-
tant regulator of epithelial proliferation, with a role in the 
pathogenesis of cancer.21 Overexpression of LMO4 in a subset 
of sporadic breast tumors was found to be a mechanism of 
BRCA1 down-regulation that may contribute to the pathogen-
esis of breast cancer.23
CtIP is a transcriptional coregulator that binds a number 
of proteins involved in cell-cycle control and cell develop-
ment, including BRCA1 and LMO4.24 CtIP represses transcrip-
tion when recruited to a promoter by the Gal4 DNA-binding 
domain, suggesting that it is a corepressor.25 Moreover, it has 
been reported to repress BRCA1-mediated transactivation of 
the p21 promoter when recruited to a Gal4-dependent pro-
moter.26 Although LMO4 interacts with two regions of CtIP, 
it does not further repress transcription by CtIP on the Gal4 
promoter, in contrast to its effect on BRCA1 activity.27
To shed further light on the potential effect of the 
gene expression of BRCA1, LMO4 and CtIP on outcome to 
EGFR TKIs, we have examined the mRNA expression of 
LMO4 and CtIP in pretreatment tumor samples of erlotinb-
treated NSCLC patients with EGFR mutations for whom data 
on BRCA1 expression and the EGFR T790M mutation were 
available. Gene expression data were correlated with clinical 
characteristics and outcome, type of EGFR activating muta-
tion (deletions in exon 19 or missense mutations in exon 21), 
and T790M mutational status.
MATERIALS AND METHODS
Tumor Samples
The Spanish Lung Adenocarcinoma Data Base had pro-
spectively screened 2105 NSCLC patient tumor tissues from 
91 institutions for EGFR mutations. EGFR mutations were 
detected in 350 patients, 217 of whom were treated with erlo-
tinib.28 Additional genetic analyses were performed in 91 of 
these patients from whom sufficient tumor tissue was avail-
able. All patients signed a written consent form, and approval 
was obtained from the Institutional Review Board and the 
Ethics Committee of each hospital.
All analyses were performed centrally at the Pangaea 
Biotech Laboratory of Molecular Biology, an ISO 15189-cer-
tified laboratory. All specimens were formalin-fixed, paraffin-
embedded tumor tissues; these were stained with hematoxilin 
and eosin and assessed by the pathologist of the Pangaea 
Biotech Laboratory. The histopathological analysis of the 
tumors, based on the 2004 World Health Organization clas-
sification of lung tumors, identified 70 adenocarcinomas, 14 
bronchioloalveolar carcinomas, and seven undifferentiated 
large-cell carcinomas.
Gene Expression Analysis
Microdissection was performed as previously 
described.18 Gene expression profiling was performed on 
RNA isolated from the tumor tissue specimens. RNA extrac-
tion, retrotranscription analysis, and real-time polymerase 
chain reaction were performed as previously described.18 The 
primer and probe sets were designed using Primer Express 
2.0 Software (Applied Biosystems, Foster City, CA) accord-
ing to their specifications in Ref Seq in http://www.ncbi.nlm.
nih.gov/LocusLink.
Statistical Analyses
Using the median as cutoff, gene expression levels 
were divided into low and high expression for the purpose 
of correlation with clinical outcome. Expression levels of 
BRCA1, LMO4, and CtIP were correlated with the Spearman 
rho test. The χ2 test or Fisher’s exact test was used to 
compare qualitative variables. The normality of quantitative 
variables was analyzed by the Kolmogorov-Smirnov test and 
compared by Student’s t test, ANOVA or the Mann–Whitney 
and Kruskal–Wallis test. Distributions were estimated with 
the Kaplan–Meier method, and compared with the log-
rank test; Binomial distribution was used to calculate 95% 
confidence intervals (CIs). A multivariate analysis was 
performed including age, sex, performance status, smoking 
history, metastatic site, type of EGFR mutation (exon 19 
deletion or L858R), erlotinib treatment line, T790M mutation 
status, and median expression levels of BRCA1, LMO4, and 
CtIP. HRs and 95% CIs were estimated with the use of the 
Cox proportional-hazards model. All statistical calculations 
were performed with the SPSS software statistical package, 
version 17.0 (SPSS Inc., Chicago, IL) and S-PLUS 6.1. 
Statistical significance was set at two-sided p value less 
than 0.05.
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RESULTS
Patient Characteristics and 
Gene Expression Levels
The characteristics of the 91 patients are shown in Table 1  
and in Tables S1 and S2, (Supplemental Digital Content 1 
and 2, http://links.lww.com/JTO/A408, which show patient 
characteristics according to LMO4 and CtIP expression levels). 
The majority of the patients (98.9%) were whites, 70.3% women, 
67% never-smokers, and 76.9% had adenocarcinoma. Deletions 
in exon 19 were more frequent (62.6%) than L858R mutation 
(37.4%). The concomitant EGFR T790M mutation was detected 
in 35 of 91 patients (38.5%). All patients were treated with 
erlotinib, 49 as first-line and 42 as second-line therapy. The overall 
response rate was 70.4%, including 14.8% complete responses.
mRNA expression of LMO4 and CtIP was successfully 
analyzed in 65 patients (71.4%) and 77 patients (84.6%), respec-
tively. The median mRNA expression was 1.54 (range, 1.51–
9.21) for LMO4 and 1.54 (range, 0.24–2.89) for CtIP. Data on 
BRCA1 expression were available in 55 patients (60.4%); the 
median mRNA expression was 7.26 (range, 1.45–20.99). There 
was a strong correlation between BRCA1 and LMO4 expres-
sion levels (ρ = 0.32; p = 0.02) and between BRCA1 and CtIP 
expression levels (ρ = 0.31; p = 0.001) but not between CtIP 
and LMO4 expression levels (ρ = 0.09; p = 0.49).
Among patients with low LMO4 expression, the fre-
quency of the concomitant T790M mutation (57.6%) was higher 
than among those with high LMO4 expression (25%; p = 0.01). 
No other differences were observed in clinical characteristics 
according to the expression levels of any of the three genes.
Gene Expression Levels and Clinical Outcome
We have previously reported that low levels of BRCA1 
mRNA correlated with a prolonged PFS of 27 months, whereas 
a shorter disease-free survival of 11 months was associated with 
high levels of BRCA1 (p < 0.03).18 In the present study, PFS 
was 13 months (95% CI, 6.7–19.3) in patients with low LMO4 
levels and was not reached for those with high LMO4 levels 
(p = 0.006; Fig. 1). In the multivariate analysis, the presence of 
high BRCA1 levels (HR, 5.13; p < 0.02) and low LMO4 levels 
(HR, 6.02; p < 0.01) emerged as markers of shorter PFS (Table 2).
There was a similar, but nonsignificant, trend toward 
shorter overall survival in patients with low levels of LMO4 
(p = 0.17) (see Fig. S1, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A408, which shows overall survival 
according to LMO4 levels).
No significant differences in median PFS or overall 
survival were observed according to CtIP expression levels 
(see Fig. S2, Supplemental Digital Content 4, http://links.lww.
com/JTO/A408, which shows PFS according to CtIP levels).
Among the 28 patients with low BRCA1 expression, 
median PFS was 19 months (95% CI, 12.7–25.3) in those 
with low LMO4 levels and not reached in those with high 
LMO4 levels (p = 0.04; Fig. 2A). Among the 27 patients with 
high BRCA1 expression, median PFS was 8 months (95% CI, 
2.9–13) in those with low LMO4 levels, and 18 months in 
those with high LMO4 levels (p = 0.03; Fig. 2B). Similar, but 
nonsignificant, results were observed for overall survival (see 
Figs. S3 and S4, Supplemental Digital Content 5 and 6, http://
links.lww.com/JTO/A408, which show overall survival in 
patients with low [Fig. S3] and high [Fig. S4] BRCA1 expres-
sion according to LMO4 levels).
No significant correlation was found between mRNA 
expression levels of any of the three genes and response (data 
not shown).
TABLE 1.  Patient Characteristics
All patients  
N = 91  
n (%)
Age, yr
 Median (range) 68 (22–85)
Sex
 Male 27 (29.7)
 Female 64 (70.3)
Race
 Asian 1 (1.1)
 White 90 (98.9)
Smoking history
 Exsmoker 24 (26.4)
 Current smoker 6 (6.6)
 Never-smoker 61 (67)
ECOG PS
 0 28 (30.8)
 1 45 (49.5)
 ≥2 17 (18.7)
Histology
 Adenocarcinoma 70 (76.9)
 Bronchioalveolar carcinoma 14 (15.4)
 Large-cell carcinoma 7 (7.7)
Stage
 IIIB 6 (6.6)
 IV 85 (93.4)
Treatment line
 First 49 (53.8)
 Second 42 (46.2)
T790M mutation
 Detected 35 (38.5)
 Not detected 56 (61.5)
EGFR mutation
 Exon 19 deletion 57 (62.6)
 L858R 34 (37.4)
Response
  CR 12 (14.8)
  PR 45 (55.6)
 CR + PR 57 (70.4)
  SD 16 (19.8)
  PD 8 (9.9)
Response
 CR+PR 57 (70.4)
 SD+PD 24 (29.6)
ECOG PS, Eastern Cooperative Oncology Group performance status; CR, complete 
response; PR, partial response; SD, stable disease; PD, progressive disease.
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Both BRCA1 and LMO4 expression emerged as signifi-
cant factors for PFS in the multivariate analysis (HR for high 
BRCA1 levels, 5.23; 95% CI, 1.57–17.45; p = 0.007; HR for 
low LMO4 levels, 4.31; 95% CI, 1.69–10.7; p = 0.002).
DISCUSSION
Notwithstanding the success of erlotinib and gefi-
tinib in cases of NSCLC with activating EGFR mutations, 
patients eventually progress despite such treatment. Erlotinib 
can cause double-strand breaks that are repaired mainly by 
homologous recombination, where BRCA1 plays an impor-
tant role, and in experimental models, erlotinib sensitivity 
is highly influenced by BRCA1 status.18 We have previously 
reported that elevated BRCA1 mRNA levels predict poor 
prognosis in resected NSCLC16 and shorter PFS to erlotinib 
in metastatic EGFR-mutant NSCLC patients.18 In the present 
study, based on the expression of genes involved in DNA-
repair pathways, we have defined a favorable subgroup of 
EGFR-mutant NSCLC patients with impressively longer 
PFS to erlotinib.
LMO4, initially described as a human breast tumor 
autoantigen, is a repressor of BRCA1-mediated transcriptional 
activity, with a potential role as a negative regulator of BRCA1 
function in sporadic breast cancers.27 Deregulation of LMO4 
occurs in several tumors, and high LMO4 nuclear expression 
is an independent prognostic factor in breast cancer.27 LMO4 
interacts with the cofactor CtIP and BRCA, and inhibits 
the transcriptional activity of BRCA1 in both yeast and 
mammalian cells.27 Immunohistochemistry studies have 
shown that LMO4 is highly expressed in epithelial tissues, 
specifically in cells lining the airways of the developing and 
adult lung.29 In a large cohort of patients with primary operable 
squamous cell carcinoma of the anterior tongue, treated with 
surgery and adjuvant radiotherapy, low LMO4 expression (by 
immunohistochemistry) was observed in 34%. However, this 
was not significantly associated with disease-free survival or 
overall survival.22
Of the 91 erlotinib-treated EGFR-mutant NSCLC 
patients included in the present study, those with low BRCA1 
expression had significantly longer PFS, as did those with 
high LMO4 expression, whereas low LMO4 levels were asso-
ciated with shorter PFS, which is consistent with findings in 
breast cancer and squamous cell carcinoma of the anterior 
tongue.22,27 Moreover, the combination of low BRCA1 and 
high LMO4 mRNA levels identified a favorable subgroup of 
patients in whom PFS was not reached. In addition, although 
overall patients with high BRCA1 levels had shorter PFS, the 
17 patients with high levels of both BRCA1 and LMO4 had a 
significantly longer PFS of 18 months and a trend toward bet-
ter overall survival.
Although a correlation was found between BRCA1, 
LMO4, and CtIP mRNA levels, no differences in median PFS 
or overall survival were observed according to CtIP expression 
levels. Intriguingly, the concomitant EGFR T790M mutation 
has been identified in approximately 30% of patients before 
treatment.11,18,30 In the present study, median PFS for patients 
with EGFR T790M mutation was 12 months, and 23 months 
for those without the T790M mutation (p = 0.01). Overall 
survival was 27 months for the subgroup with positive T790M, 
and 33 months for the subgroup negative for T790M (p = 
0.12). Overall response rate for the T790M positive subgroup 
was 55.6%, and 73.3% for the negative subgroup (p = 0.17). 
The frequency of T790M mutations was 57.6% in patients 
with low LMO4 expression, although in the multivariate 
analysis, the presence of the T790M mutation (HR, 2.25; p = 
0.29) was not a marker of shorter PFS. A positive correlation 
between BRCA1 and LMO4 levels was found (ρ = 0.32, p = 
0.02). Intriguingly, LMO4 levels were lower in the subgroup of 
patients with the presence of T790M in comparison with the 
subgroup negative for T790M (p = 0.03). No differences were 
observed in BRCA1 mRNA levels according to T790M status 
(p = 0.47). The relationship between the T790M mutation and 
LMO4 expression warrants further study.
TABLE 2.  Multivariate Analysis
HR 95% CI p
BRCA1
 ≤4.92 1
 4.92–10.7 5.32 1.45–19.52 0.03
 >10.7 5.13 1.25–20.99 0.02
CtIP
 ≤1.21 1
 1.21–2.1 0.69 0.24–2.02 0.50
 >2.1 1.10 0.42–2.89 0.84
LMO4
 ≤1.29 6.02 1.51–23.94 0.01
 1.29–1.86 2.81 0.85–9.21 0.09
 >1.86 1
HR, hazard ratio; BRCA1, breast cancer gene 1; LMO4, Lin11, Isl-1 and Mec-3 
domain only 4; CtIP, C terminus-binding protein–interacting protein.
FIGURE 1.  Progression-free survival to erlotinib in 65 non–
small cell lung cancer patients according to LMO4 expression 
levels. CI, confidence interval; PFS, progression free survival; 
LMO4, Lin11, Isl-1 and Mec-3 domain only 4.
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Although the sample size in this study was relatively 
small, which may possibly explain the lack of significant dif-
ferences in response rate and overall survival according to 
BRCA1 and LMO4 expression levels, the finding that low 
BRCA1 and high LMO4 levels were associated with lon-
ger PFS indicates that a potential two-gene model based on 
BRCA1 and LMO4 expression merits further investigation to 
confirm its role in predicting the efficacy of EGFR TKIs in 
lung adenocarcinomas with EGFR mutations.
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